KMTSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends April 30
KESTRA MEDICAL TECHNOLOGIES, LTD.
Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026
$29.37+2.13 (+7.82%)
Close on Oct 19, 2026
- Market cap
- $1.72B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2023 to 2026
Gross margin
51.4%
Operating margin
-141.6%
Net margin
-138.4%
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +59.0% | – | – | – | |
| Gross profit | +101.8% | – | – | – |
Returns and balance sheet
4 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2023 | FY2023 | FY2026 | Trend |
|---|---|---|---|---|
| Return on assets | – | – | -40.2% | |
| Current ratio | – | – | 4.41 | |
| Net debt to EBITDA | – | – | 0.45× | |
| Interest coverage | – | – | -17.9× | |
| Capex to revenue | – | – | 36.7% | |
| Diluted shares | – | – | 54M |
Cash use needs five years of cash flow figures
Kestra Medical Technologies does not report operating cash flow and capital expenditure for each of the last five fiscal years.
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
4of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$131.61M
- Cash generatingOperating cash flow above zero-$81.70M
- Return on assets improvedROA up on the prior year-247.7% → -44.5%
- Earnings backed by cashOperating cash flow above net income-$81.70M vs -$131.61M
- Less leverageLong-term debt to assets fell13.9% → 11.9%
- Better liquidityCurrent ratio rose6.72 → 4.41
- No dilutionShare count did not rise25M → 54M
- Gross margin improvedGross margin up on the prior year40.47% → 51.37%
- More efficientAsset turnover rose1.30 → 0.32